PHARMACIST MANAGEMENT OF A HYPERLIPIDEMIA CLINIC

被引:25
作者
FURMAGA, EM [1 ]
机构
[1] VET AFFAIRS W SIDE MED CTR,CHICAGO,IL
来源
AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1993年 / 50卷 / 01期
关键词
ADMINISTRATION; AMBULATORY CARE; ANTILIPEMIC AGENTS; CLINICAL PHARMACY; COMPLIANCE; DRUG ADMINISTRATION; DRUGS; HYPERLIPIDEMIA; MECHANISM OF ACTION; PATIENT INFORMATION; PHARMACISTS; HOSPITAL; PRESCRIBING; TOXICITY;
D O I
10.1093/ajhp/50.1.91
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A hyperlipidemia clinic in which a pharmacist provides primary care is described. The clinic was established at a Veterans Affairs medical center in january 1990. A pharmacist performs limited physical assessments, refers patients to other clinics as necessary, orders laboratory and diagnostic tests, and selects and monitors the use of lipid-lowering medications. Interventions are performed according to the pharmacist's clinical judgment; there is no set protocol. Recommendations for patient management are approved by an attending physician, who prescribes the antilipemic drugs. The pharmacist teaches patients about hyperlipidemia, the impact of diet and lifestyle, and the mechanism of action, administration, and adverse effects of the antilipemics prescribed. The pharmacist also monitors compliance, laboratory test values, and the response to treatment. Treatment is modeled after the recommendations of the National Cholesterol Education Program. If a patient has not achieved the targeted cholesterol concentration after receiving dietary therapy for three months, further education about diet and lifestyle is provided. If, after three more months, the cholesterol level remains high, drug therapy is begun. Four antilipemic drugs-colestipol, gemfibrozil, lovastatin, and niacin-are used in the clinic. Since it began operating, the clinic has enrolled 284 patients. Compliance with the lipid-lowering agents has ranged from 43% to 100%. Adverse effects have accounted for the majority of cases of noncompliance. A pharmacist provides primary care for patients with hyperlipidemia in an ambulatory-care clinic.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 21 条
[1]   MOVING TOWARD THE PROVISION OF COMPREHENSIVE AMBULATORY-CARE PHARMACEUTICAL SERVICES [J].
ABRAMOWITZ, PW ;
MANSUR, JM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (05) :1155-1163
[2]   BILE-ACID SEQUESTRANTS [J].
AST, M ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :99-106
[3]   SUSTAINED IMPROVEMENT IN DRUG DOCUMENTATION, COMPLIANCE, AND DISEASE-CONTROL - A 4-YEAR ANALYSIS OF AN AMBULATORY CARE MODEL [J].
BOND, CA ;
MONSON, R .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (06) :1159-1162
[4]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[5]  
CUMMINGS DM, 1984, AM J PHARM, V156, P44
[6]   ESTABLISHMENT AND EVALUATION OF A SERUM-CHOLESTEROL MONITORING SERVICE IN A COMMUNITY PHARMACY [J].
EINARSON, TR ;
BOOTMAN, JL ;
MCGHAN, WF ;
LARSON, LN ;
GARDNER, ME ;
DONOHUE, M .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (01) :45-48
[7]   THE DECLINE IN ISCHEMIC-HEART-DISEASE MORTALITY-RATES - AN ANALYSIS OF THE COMPARATIVE EFFECTS OF MEDICAL INTERVENTIONS AND CHANGES IN LIFESTYLE [J].
GOLDMAN, L ;
COOK, EF .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (06) :825-836
[8]   COST-JUSTIFICATION OF A CLINICAL PHARMACIST-MANAGED ANTICOAGULATION CLINIC [J].
GRAY, DR ;
GARABEDIANRUFFALO, SM ;
CHRETIEN, SD .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (7-8) :575-580
[9]   RECHALLENGE WITH CRYSTALLINE NIACIN AFTER DRUG-INDUCED HEPATITIS FROM SUSTAINED-RELEASE NIACIN [J].
HENKIN, Y ;
JOHNSON, KC ;
SEGREST, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (02) :241-243
[10]   LIPID-LOWERING DRUGS - AN OVERVIEW OF INDICATIONS AND OPTIMUM THERAPEUTIC USE [J].
ILLINGWORTH, DR .
DRUGS, 1987, 33 (03) :259-279